and ensure a drug-free campus, the School of International Exchange at Ningbo University is organizing the"Prevention is Better than Cure, Stay Healthy at NBU" Anti-Drug Poster Design Competition. This initiative aims to help...
179 POSTER Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors... (2008) Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients ...
Anti-drug poster contest winners convey powerful message.(Neighbor)Hitzeman, Harry
These include but are not limited to anti-scarring dressings, post-surgery antiadhesion membranes, and drug delivery carrier implants. However, it should be noted that some limitations exist in the current study. First, we used a two-step method for CS-OI coating onto nanofibers, during which...
diuretics and beta-blockers were also found in variety of water samples. A U.S. Environmental Protection Agencyposter presentationdemonstrated how drugs banned in sport could infiltrate crops irrigated with treated wastewater. This highlights the unfortunate reality that not all drug residues are removed...
2022, Nature Reviews Clinical Oncology Loncastuximab Tesirine: First Approval 2021, Drugs Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy 2021, Expert Opinion on Biological Therapy View all citing articles on Scopus Presented as a poster (interim data)...
About 4SC 4SC AGis a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises three ...
Fig. 1: Cisplatin chitosan nanoparticles (CDDP-NP) demonstrate improved local drug retention and induce potent anti-tumor response in FaDu tumor bearing mice xenografts. A Schematic representation of the experiment. B Nude mice xenografts bearing subcutaneous human FaDu HNSCC cell line induced tumors ...
Bardia et al., “Safety and tumor responses of the anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in refractory, metastatic, triple-negative breast cancer (TNBC): An ongoing Phase II trial”, Poster presented at AACR-NCI-EORTC International Conference: Molecular Targets...
consequently making it a very attractive drug target. Several succinate receptor ligands have been described, including the succinate receptor agoniztscis-epoxysuccinic acid (cESA) andcis-1,2-cyclopropanedicarboxylic acid (cCPDA) which both demonstrate an efficacy similar to that of endogenous succinate...